Market News
Recent Developments
Product Approvals
- In March 2022, UCB S.A., a pharmaceutical company, announced the U.S. Food and Drug Administration (FDA) approval for FINTEPLA (fenfluramine) oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome in patients two years of age and older. LGS is a severe childhood-onset developmental and epileptic encephalopathy (DEE) characterized by drug-refractory seizures with high morbidity as well as serious impairment of neurodevelopmental, cognitive, and motor functions.
- In January, 2020, Eisai Co., Ltd., a pharmaceutical company, announced the approval of supplementary new drug applications in Japan for its in-house developed antiepileptic drug (AED), Fycompa (perampanel) for an additional indication for monotherapy of partial-onset seizures and an additional indication for partial-onset seizures in pediatric patients aged 4 years and older, as well as a new fine granule formulation.
Acquisitions and agreements
- On January 25, 2023, Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, announced that it has completed the acquisition of the U.S. rights for FYCOMPA (perampanel) CIII, from Eisai Co., Ltd, a pharmaceutical company. The acquisition provides Catalyst Pharmaceuticals, Inc. with an increased U.S. commercial presence in neurology and an expanded product portfolio with an established, first-in-class, commercial stage epilepsy asset.
- In March 2021, Eisai Co., Ltd., a pharmaceutical company, announced that it had entered into an agreement with Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, to transfer the U.S. commercial rights for the anti-epileptic drug (AED) Fycompa (generic name: perampanel). The agreement will provide the opportunity for Eisai’s neuroscience team to focus on its long-term strategic priorities on the research, development, and commercialization of its Alzheimer’s disease portfolio.
U.S.: 
U.K. : 
India : 
